CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer
- 14 February 2022
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 126 (11) , 1581-1588
Abstract
Background CD103+CD8+ tissue-resident memory T (TRM) cells, associated with better overall survival among various malignancies, are thought to activate anti-tumour immune response and affect therapeutic sensitivity including both immunotherapy and adjuvant chemotherapy (ACT). Methods Totally 650 muscle-invasive bladder cancer (MIBC) patients from three independent cohorts were included in this study for survival and cisplatin-based ACT response analysis. Another public data set consisting of 195 patients from IMvigor210 trial receiving PD-L1 blockade were involved in the assessment of immunotherapeutic response. Fifty-nine fresh tumour tissues were used to evaluate immune infiltration of CD103+CD8+ TRM cells. Results Patients with high CD103+CD8+ TRM cells infiltration, but not CD8+ T cells, are more likely to benefit from immunotherapy and ACT. The presence of TRM cells is highly associated with an enhanced IFNγ-enriched and T cell-inflamed anti-tumour microenvironment. Elevated CD103+CD8+ TRM cells infiltration correlated with superior ACT response in mismatch repair (MMR), homologous recombination (HR), PIK3CA/AKT and RAS/RAF pathway proficient or histone modification and cell cycle pathway deficient patients. Conclusions CD103+CD8+ TRM cells played a crucial role in anti-tumour immunity and served as an ideal prognostic biomarker. It could be treated as a superior companion predictor for treatment response to PD-L1 inhibitor and ACT within MIBC patients.Keywords
This publication has 36 references indexed in Scilit:
- Tissue-resident memory T cells: local specialists in immune defenceNature Reviews Immunology, 2015
- PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian CancerCancer Immunology Research, 2015
- CD103 + Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the BladderJournal of Urology, 2015
- Whole–genome characterization of chemoresistant ovarian cancerNature, 2015
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer PatientsThe Journal of Immunology, 2015
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitroOncology Reports, 2012
- Natural Innate and Adaptive Immunity to CancerAnnual Review of Immunology, 2011